Mizuho analyst Graig Suvannavejh raised the firm’s price target on Immunocore (IMCR) to $37 from $36 and keeps a Neutral rating on the shares following the Q3 report.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore Holdings: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
- Immunocore presents Phase 1 data for hepatitis B candidate at AASLD
- Immunocore Reports Strong Growth in Q3 2025
- Immunocore reports Q3 EPS 0c, consensus (24c)
- Apple upgraded, Comcast downgraded: Wall Street’s top analyst calls